Cytokines reindate NK cell–mediated cancer immunosurveillance

Laurence Zitvogel1,2,3,4 and Guido Kroemer5,6,7,8

In healthy individuals, cells that lose expression of MHC class I molecules are quickly targeted for elimination by NK lymphocytes. A paradox in cancer immunology is the observation that many tumor cells often have a drastic reduction of MHC class I molecules, yet these cells are not eliminated by NK cells, as they should be. In this issue of the JCI, Ardolino et al. demonstrate that NK cells that infiltrate MHC class I–deficient tumors acquire an anergic state that can be reversed by particular combinations of exogenous cytokines. These results indicate that IL-12 plus IL-18 or a recombinant interleukin engineered to stimulate the IL-2 receptor β/γ heterodimer (but not the IL-2 receptor α/β/γ complex) have the potential to be used clinically to reindate immunosurveillance against MHC class I–deficient tumors.

MHC class I and NK cell education

NK cells are innate lymphocytes programmed to kill target cells and also secrete cytokines to modulate adaptive immunity (1). NK cells can exert their effector functions against infected and malignant target cells while maintaining self-tolerance. The threshold of NK cell responsiveness is tuned by micro-environmental cues, and adaptability of NK cells to their milieu is dictated by their “education” or “licensing” by host MHC class I molecules, which operate through interaction with NK cell inhibitory receptors (killer inhibitor receptors [KIRs]) in humans, Ly49 molecules in mice, and CD94/NKG2A dimers in both species). Hence, “uneducated” or “unlicensed” NK cells generated in MHC class I–deficient mice are defective in their response to tumor cells or antibodies that engage activating NK receptors (2). The adoptive transfer of NK cells derived from MHC class I–deficient hosts into WT, MHC class I–expressing recipients results in functional recovery and full-blown responsiveness of the NK cells. Conversely, NK cells from WT animals that are transferred into MHC class I–deficient hosts become hyporesponsive or anergic. Similarly, human NK cells that lack killer cell immunoglobulin–like receptor (KIR) display low killing and cytokine release capacities when encountering target cells (2). The most responsive subset of NK cells are those that express multiple inhibitory receptors that can be engaged by neighboring cells by means of their self-MHC class I molecules. This cardinal “rheostat concept” of NK cell licensing has been primarily demonstrated using gene knockouts and transgenic mice under steady-state conditions. It has been an open conundrum whether this concept would also apply to neoplastic diseases in which cancer cells (through genetic or epigenetic alterations) often manifest with a loss of MHC class I molecule expression, perhaps under the selective pressure of tumor antigen–reactive T lymphocytes (3).

MHC class I–deficient tumor cells induce NK cell anergy

In this issue of the JCI, Ardolino et al. (4) reveal that NK cell anergy is induced in WT mice bearing RMA-S lymphomas, which lack antigen peptide transporter 2 (Tap2) and are thereby MHC class I deficient. The anergic state of NK cells manifested as hyporesponsiveness of intratumoral NK cells ex vivo following restimulation with either plate-bound antibodies against the NK cell–activating receptors NKR-P1C or NKP46 or with YAC-1, an MHC-mismatched tumor cell line. In these conditions, RMA-S lymphoma–infiltrating NK cells failed to degranulate and release IFN-γ. NK cell anergy was an early and local phenomenon, occurring as early as seven days after tumor inoculation and only within the cancer infiltrate and in the tumor-draining lymph node. Moreover, NK cell anergy could be interpreted as a “dominant-negative” phenotype, as it was observed even in conditions in which only a minority of the tumor cells had lost MHC class I molecules (4).

Defective effector functions of RMA-S lymphoma–infiltrating NK cells could be directly ascribed to the loss of MHC class I expression in growing tumors, as RMA-S tumors in which MHC class I expression was restored via the reintroduction of Tap2 did not contain anergic NK cells. Moreover, removal of MHC class I expression by knocking out the β2 microglobulin or Tap2 genes in myeloid leukemia–derived C1498 cells promoted the
generation of tumors that were infiltrated by anergic NK lymphocytes, while MHC class I–sufficient WT C1498 tumors contained functional NK cells. Of note, the functional defect of NK cells residing in MHC class I–deficient tumors could not be ascribed to variegated surface expression of NK cell inhibitory receptors (4). The expression of MHC class I molecules failed to influence NK cell trafficking or proliferation in situ, as MHC class I–deficient or –proficient tumors contained similar proportions of tumor-residing NK cells. Finally, the NK cell anergy associated with MHC class I–deficient tumors was not due to an increase in production of immunosuppressive cytokines, such as TGF-β or IL-10, Tregs, or myeloid-derived suppressor cells (Figure 1).

Intratumoral NK cell hyporesponsiveness was associated with a dampening of early activation signals, specifically those that mediate phosphorylation of ERK1/2 (4), a mechanism previously described in NK cells differentiating in MHC class I–deficient mice or in WT NK cells invading MHC class I–proficient tumors (2). Altogether, these findings indicate that NK cells are progressively unlicensed as a consequence of the sustained loss of MHC class I molecules on cancer cells.

**Cytokines restore function in anergic NK cells**

Importantly, although NK cells derived from β2 microglobulin–deficient mice or MHC class I–deficient tumors were refractory to stimulation via cell surface–activating receptors, they were able to respond to specific cytokines, such as the combination of IL-12 plus IL-18 or H9, which is an artificial cytokine engineered to stimulate the β/γ Il-2 receptor heterodimer but not the α/β/γ IL-2 receptor complex (ref. 5 and Figure 1). Such exogenous stimuli (IL-12 plus IL-18 or H9) could restore ERK1/2 phosphorylation, IFN-γ secretion, as well as the functional capacity of NK cells to eradicate MHC class I–deficient tumors. In contrast, the growth of MHC class I–sufficient tumors was not affected by the administration of these cytokines. In this context, it is important to note that it has previously been shown that lack of NK cell licensing can be reversed by exposing NK cells to IL-12 (6) or by systemic infection of mice with *Listeria* or herpes viruses (7).

**Clinical implications**

The findings described by Ardolino et al. (4) offer a number of clinical prospects. In most human tumors, NK cells exhibit defective effector functions (8, 9). Constitutive or therapy-induced NK cell effector functions are likely to affect the clinical course of several human malignancies, including leukemia, multiple myeloma, neuroblastoma, gastrointestinal sarcoma, and kidney and lung carcinoma (10, 11).

Loss or downregulation of MHC class I expression has been widely reported in cancers that result from oncogene activation, such as those with mutations in NMYC, ε-MYC, HER2/neu, or BRAF, and in cancers associated with inhibition of the NF/κB pathway (12, 13). Moreover, MHC class I loss variants become more frequent in the tumor cell population after stimulation with tumor-specific T cells by therapeutic vaccination (14) or treatment with imatinib mesylate (15), presumably as a result of T cell–mediated immunoselection. Incidentally, it is conceivable that blocking the NK cell inhibitory receptors (for instance with lirilumab [IPH2101]) might result in a similar paradoxical inhibition of NK cell functions, as observed in the presence of MHC class I–negative target cells (16).

Combating NK cell anergy by systemic or local delivery of inflammatory signals, such as with activated dendritic cells or cytokines, could constitute a valuable therapeutic option (5). Agents that stimulate IL-2Rβ/γ signaling without preferential binding to the high-affinity IL-2Ra/β/γ complex, which is constitutively expressed on
The Journal of Clinical Investigation

Commentary

Treg cells, may effectively boost NK cells without stimulating unwarranted immunosuppressive circuits (16, 17). Multiple approaches that use IL-12 have been or are being evaluated in advanced cancers, alone or together with conventional chemotherapy or mAbs targeting growth factors. IL-12 can be administered as a recombinant protein or via plasmid electroporation as well as in replication-incompetent adenoviral vectors. IL-12 is also being developed in the context of adoptive cell transfer immunotherapy with genetically engineered tumor-infiltrating lymphocytes (18). Results from recent phase I/II trials evaluating the safety and efficacy of recombinant IL-18 (SB-485232; GlaxoSmithKline) in stage IV melanoma patients (19), alone or in combination with pegylated liposomal doxorubicin against ovarian cancers (20), suggest that IL-18 has limited anti-cancer activity as a single agent. However, pilot studies combining IL-12 and IL-18 have not yet been attempted in humans.

To our knowledge, the stratification of patient cohorts based on tumor MHC class I expression has so far not been considered in the context of immunotherapy. Given that reliable immunohistochemical methods for the detection of MHC class I molecules on cancers and CD3, CD8, FOXP3, or NKp46 on tumor-infiltrating lymphocytes are available (13, 15), it should be possible to monitor these parameters before and after administration of NK cell–stimulatory compounds or antibodies against tumor antigens that elicit potentially NK-mediated cytotoxic responses (21). We anticipate that NK immunotherapies will yield predictive biomarkers that will have an impact on the clinical management of cancer patients.

Acknowledgments

L. Zitvogel and G. Kroemer are supported by the Equipes labelisées par la Ligue contre le Cancer; the Agence Nationale de la Recherche (ANR); the Association pour la Recherche sur le Cancer (ARC); Cancérothèque Ile-de-France; the Institut National du Cancer (INCa); the Fondation Bettencourt-Schueller; the Fondation de France; the Fondation pour la Recherche Médicale (FRM); the European Commission (Art-Force); the European Research Council (ERC); LabEx Immuno-Oncology; SIRIC Stratified Oncology Cell DNA Repair and Tumor Immune Elimination (SORCATE); SIRIC Cancer Research and Personalized Medicine (CARPEM); and the Paris Alliance of Cancer Research Institutes (PACRI).

Address correspondence to: Laurence Zitvogel, INSERM U1015, CICBT507, University Paris XI, Institut Gustave Roussy, 114 rue Edouard Vaillant, Villejuif, 94805, France. Phone: 33.1.42.11.50.05; E-mail: laurence.zitvogel@gustaveroussy.fr.